The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Testing and treatment patterns in KRAS mutant mNSCLC: Results from the MYLUNG Consortium.
 
Bo Wang
Stock and Other Ownership Interests - Roche/Genentech (I)
Consulting or Advisory Role - AstraZeneca; BeiGene; EMD Serono
Speakers' Bureau - EMD Serono
 
Makenzi Evangelist
Consulting or Advisory Role - AADi; AstraZeneca; AstraZeneca; Daiichi Sankyo/Lilly; Gilead Sciences; Gilead Sciences; Mirati Therapeutics; Regeneron; Regeneron; Takeda; Takeda
 
James Butrynski
Employment - US Oncology
Consulting or Advisory Role - Boehringer Ingelheim
 
John Paschold
Consulting or Advisory Role - AstraZeneca
 
Patrick Ward
Employment - Bon Secours Mercy Health (I)
Consulting or Advisory Role - Amgen; AstraZeneca; AZ/DSI; Daiichi Sankyo/Astra Zeneca; Fresenius Kabi BioSimilars; MDoutlook; NEUVOGEN
Travel, Accommodations, Expenses - Neuvogen; Sarah Cannon Research Institute
 
David Hakimian
Honoraria - CVS Health
 
Robert Jotte
Leadership - Sarah Cannon Research Institute
Consulting or Advisory Role - AstraZeneca
 
Michael Meshad
No Relationships to Disclose
 
Donald Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Marcus Neubauer
Employment - McKesson/US Oncology Network
Leadership - McKesson
Travel, Accommodations, Expenses - McKesson
 
Nicholas Robert
Employment - McKesson
Leadership - McKesson
Stock and Other Ownership Interests - McKesson; Moderna Therapeutics; Oncolytics (I)
 
Jennifer Yori
No Relationships to Disclose
 
Manoj Pant
No Relationships to Disclose
 
Robert Coleman
Employment - US Oncology; Vaniam Group
Stock and Other Ownership Interests - McKesson/US Oncology Network
Consulting or Advisory Role - Abbvie; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck
Research Funding - Alkermes; AstraZeneca/MedImmune; Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck; Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); ModeX Therapeutics (Inst); Novartis (Inst); Novocure (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
David Waterhouse
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AVEO; AZTherapies; Bayer; Bristol-Myers Squibb; Daiichi; Eisai; EMD Serono; Exelixis; Fresenius Kabi; Gilead Sciences; Janssen Oncology; Lilly; McGivney Global Advisors; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi; Sanofi/Regeneron; Seagen; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb